Streetbeat News

Regulatory

HROW

Harrow has announced the manufacture of the first of three commercial-scale Process Performance Qualification (PPQ) batches of Triesence, a product used for visualization during vitrectomy and ocular inflammatory conditions. The second and third required PPQ batches are scheduled.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:27 am

DJT

Trump Media & Technology Group shares are trading lower after the SEC declared effectiveness of the registration statement on Form S-1 related to the resale by certain securityholders of certain shares and warrants.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:25 am

MNMD

MindMed has completed an end-of-phase 2 meeting with the FDA and reached alignment on the Phase 3 development strategy for MM120 in treating Generalized Anxiety Disorder (GAD). The company plans to initiate the Phase 3 clinical program in the second half of this year.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:13 am

EWU

The Bank of England has decided to leave the bank rate unchanged at 5.25%. This decision may have implications for various financial markets and instruments, including the iShares MSCI United Kingdom ETF (EWU).

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:12 am

ATAI

Atai Life Sciences announced an update on Beckley Psytech's Phase 1/2A trial of ELE-101 for Major Depressive Disorder. Initial Phase 1 results were positive, and the first patients have been dosed in Phase 2A. Results are expected in H2 2024.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:05 am

META

A report reveals that Instagram's algorithm continues to recommend sexually explicit content to teen accounts, despite Meta's promises to provide an age-appropriate experience. Tests showed that within minutes of logging in, teens were exposed to adult content. Meta dismissed the findings as unrepresentative. Similar tests on Snapchat and TikTok did not yield the same results.

Portfolio Pulse from Benzinga Neuro

June 20, 2024 | 10:48 am

PTCT

PTC Therapeutics shared interim results from its Phase 2 PIVOT-HD study of PTC518 in Huntington's Disease, showing dose-dependent lowering of mutant huntingtin protein in blood/cerebrospinal fluid and favorable trends on several relevant clinical assessments. The FDA has lifted the partial clinical hold on PTC518 based on the PIVOT-HD data.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 10:34 am

EQNR

ICOW

PWER

The Australian government has granted Equinor ASA and Oceanex Energy a feasibility license for an offshore wind project off the east coast. The project, if feasible, could generate over 2 GW of electricity. This move aligns with Australia's goal to reach net zero emissions by 2050.

Portfolio Pulse from Lekha Gupta

June 20, 2024 | 10:33 am

NIO

NIO Inc. (NYSE:NIO) CEO William Li has expressed opposition to the European Union's newly imposed tariffs on Chinese electric vehicles (EVs). Despite the tariffs, NIO's upcoming Firefly models are expected to remain competitive in the European market. The EU plans to impose additional tariffs up to 38.1% on Chinese EVs, with an average of 21% for companies like NIO. A final decision on the tariffs is expected by October or November.

Portfolio Pulse from Nabaparna Bhattacharya

June 20, 2024 | 10:19 am

NUTX

Nutex Health has received shareholder approval for a reverse stock split ranging from 1-for-2 to 1-for-16, aiming to comply with NASDAQ listing requirements.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 10:15 am